Pulmonary arterial hypertension pah market
Pulmonary Arterial Hypertension Drug Market, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
- Aug 2022
- CMI203
- 163 Pages
- Excel & Pdf
- Pharmaceutical
Pulmonary Hypertension (PH) is a rare disease that affects the pulmonary arteries. High blood pressure in the lungs is called pulmonary arterial hypertension (PAH) or pulmonary hypertension (PH). It is characterized by narrowed and blocked arteries and capillaries. This rare disease usually worsens over time and can lead to death if left untreated. Due to the increase in the incidence of PAH (pulmonary arterial hypertension), the increase in the geriatric population, and the increasing government support for the development of orphan drugs, the market is expected to witness significant growth during the forecast period.
The global pulmonary arterial hypertension drug market is estimated to be valued at US$ 7,310.1 Million in 2022 and is expected to reach US$ 11,220.2 million by 2030, at a CAGR of 5.5% during the forecast period (2022–2030).
Figure 1. Global Pulmonary Arterial Hypertension Drug Market Share (%), By Region, 2022
An increasing number of heart failure causes pulmonary arterial hypertension (PH) cases, which is expected to increase significantly during the forecast period.
The pulmonary arterial hypertension drug market is expected to see significant growth during the forecast period as the number of heart failures continues to rise, which then leads to cases of pulmonary arterial hypertension (PAH). For instance, in 2019, Heart Failure Society of America reported that there are approximately 550,000 newly diagnosed heart failure cases in the U.S. each year, and nearly 1.4 million congestive heart failure (CHF) patients are under 60 years of age.
Pulmonary Arterial Hypertension Drug Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 7,310.1 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 5.5% | 2030 Value Projection: | US$ 11,220.2 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2. Global Pulmonary Arterial Hypertension Drug Market Share, By Drug Class, 2022
Increasing collaboration for the development of novel products is expected to drive growth of pulmonary arterial hypertension drug market over the forecast period.
Key players are focusing on collaborations and mergers to develop new products for the pulmonary arterial hypertension (PAH) market, which is expected to promote pulmonary arterial hypertension drug market growth during the forecast period. For example, in 2017, Bayer AG, a German multinational pharmaceutical and Life Sciences Company and Vectura Group Plc., a British pharmaceuticals business, expanded their collaboration to develop an improved version of the Breelib nebulizer, which improves the efficacy of iloprost aerosol in the treatment of pulmonary atrial hypertension.
Global Pulmonary Arterial Hypertension Drug Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 9, 2022, are approximately 583,038,110 confirmed cases with 6,416,023 deaths. The Coronavirus (COVID-19) outbreak started from Wuhan, China and has spread across continents, affecting various industries globally.
Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, U.A.E., Egypt, and others are facing problems with regards to transportation of drugs from one place to another. However, the crisis due to coronavirus disease has given a boost to pharmaceutical companies to grow and develop an ambitious drug and vaccine projects with a sole aim to contain the viral outbreak. Such demanding R&D projects are in turn creating a wealth of opportunities for innovations in global pulmonary arterial hypertension drug market.
Global Pulmonary Arterial Hypertension Drug Market: Restraint
Factors such as expiration of key molecule patents, drug-related side effects such as gastric ulcers, hypotension, congestive heart failure, lack of awareness among people in emerging countries such as India Brazil, China and others, and high costs of diagnosis and treatment are expected to hamper the global pulmonary arterial hypertension drug market growth.
Key Players
Major players operating in the global pulmonary arterial hypertension drug market include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Market Opportunity Map
- Report Description
- Global Pulmonary Arterial Hypertension Drug Market Insights
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Merger & Acquisitions
- Product Launch
- Epidemiology
- Pipeline Analysis
- New Product Launches
- Pest Analysis
- Global Pulmonary Arterial Hypertension Drug Market - Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Epidemiology
- Impact on Drug Development
- Global Pulmonary Arterial Hypertension Drug Market, By Drug Class, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Endothelin Receptor Antagonists (ERAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Soluble Guanylate Cyclase (sGC) Stimulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Prostacyclin Analogue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Introduction
- Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Inhaled
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Pulmonary Arterial Hypertension Drug Market, By Region, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017–2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017–2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017–2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017–2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017–2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017–2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Region/Country, 2017–2030, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Snapshot
- Company Profiles
- United Therapeutics Corporation
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Actelion Pharmaceuticals Ltd
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Arena Pharmaceuticals
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Daiichi Sankyo Company, Limited.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sandoz AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- United Therapeutics Corporation
- Company Profiles
- Section
- Research Methodology
- About us
*Browse 35 market data tables and 34 figures on “Global Pulmonary Arterial Hypertension Drug Market” - forecast to 2030
Detailed Segmentation:
- Global Pulmonary arterial hypertension Drug Market, By Drug Class:
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Prostacyclin Analogue
- Calcium Channel Blockers
- Others
- Global Pulmonary arterial hypertension Drug Market, By Route of Administration:
- Oral
- Inhaled
- Intravenous
- Subcutaneous
- Global Pulmonary arterial hypertension Drug Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Pulmonary arterial hypertension Drug Market, By Region:
- North America
- By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Prostacyclin Analogue
- Calcium Channel Blockers
- Others
- By Route of Administration
- Oral
- Inhaled
- Intravenous
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- By Drug Class
- Latin America
- By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Prostacyclin Analogue
- Calcium Channel Blockers
- Others
- By Route of Administration
- Oral
- Inhaled
- Intravenous
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class
- Europe
- By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Prostacyclin Analogue
- Calcium Channel Blockers
- Others
- By Route of Administration
- Oral
- Inhaled
- Intravenous
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Drug Class
- Asia Pacific
- By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Prostacyclin Analogue
- Calcium Channel Blockers
- Others
- By Route of Administration
- Oral
- Inhaled
- Intravenous
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drug Class
- Middle East
- By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Prostacyclin Analogue
- Calcium Channel Blockers
- Others
- By Route of Administration
- Oral
- Inhaled
- Intravenous
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- By Drug Class
- Africa
- By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Prostacyclin Analogue
- Calcium Channel Blockers
- Others
- By Route of Administration
- Oral
- Inhaled
- Intravenous
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Drug Class
- North America